Light-Induced Chemotherapy (LICHT)

Over the past forty years, significant advances in chemotherapy have greatly improved treatment for a variety of cancers.  Yet, all of the current chemotherapeutic drugs have very serious side effects which greatly impact quality of life.  For example, patients undergoing chemotherapy often suffer from temporary alopecia (hair loss), persistent nausea, and intense vomiting.  Chemotherapy also suppresses the immune system and makes patients more susceptible to disease and infection.

Toxicity is another major problem with chemotherapeutic drugs as it is difficult to minimize the damage done to normal tissues and organs with current methods of drug delivery.  Therefore, one of the biggest challenges has been finding a new treatment for cancer which selectively targets and kills tumor cells with little or no effect on normal tissues and organs.

DAYA has invented a revolutionary new technology called “Light-Induced Chemotherapy” (LICHT) for the treatment of cancer in tissues that are accessible to visible light.  Hence, LICHT will be extremely useful for treating certain types of cancer such as:  colon, skin, lung, bladder, esophagus, ovarian, cervical, and uterine.  LICHT can also be used to treat other diseases including bacterial and viral infections.

DAYA is currently using LICHT to develop safe and effective treatments for colorectal and ovarian cancers.  This technology involves a three-component ensemble (bioconjugate) which is designed to allow the chemotherapeutic drug to accumulate in the colorectal or ovarian tumor.  The tumor is then exposed to visible light which releases the chemotherapeutic drug.  As a result, the chemotherapeutic drug selectively kills the cancer cells within the tumor.

LICHT effectively eliminates the problem of toxicity because the bioconjugate is completely inactive when not exposed to light.  Moreover, the unreleased chemotherapeutic drug remains bound to the rest of the bioconjugate, and it is eventually cleared from the body.

DAYA is seeking a commercial partner to introduce this new propriety technology into the market.